H.R. 10164, Supply-Chain Transparency & Regulatory Coordination. Quorum's AI analysis reads it as a net benefit — and names who gains.

What it does

This bill directs the Secretary of Commerce to designate a senior official to lead a coordinated federal effort promoting U.S. biomanufacturing competitiveness. The official will identify supply-chain vulnerabilities, regulatory barriers, and foreign-adversary dependencies in critical biomanufacturing inputs; map federal commercialization processes; consolidate public resources; and report biennially to Congress. The bill creates no new funding, mandates, or restrictions on private industry—it is a transparency and coordination mechanism designed to reduce regulatory friction and strengthen domestic production capacity in biotechnology manufacturing.

The analysis names domestic biomanufacturing companies and suppliers — and 3 more groups — among the beneficiaries.

The trade-off

The bill's focus on 'foreign adversary' dependencies may indirectly prioritize reshoring of biomanufacturing to the U.S., potentially raising costs for companies currently reliant on lower-cost foreign suppliers—a benefit to domestic producers but a cost to consumers if passed through.

Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.

Who is behind it

Filed by Robert Latta. Cosponsored by Debbie Dingell.